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Summary for electronic table of contents 
 
This is a contemporary retrospective cohort study describing the characteristics, health care utilization and 
outcome of young adults with heart failure (HF) using the link administrative databases in Alberta. A total of 
34 548 patients with HF were identified between 2002 and 2014. We found that mortality in young adults 
with HF remains high with frequent hospitalization.  
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Abstract 
 
Background. Data on young patients with heart failure (HF) are sparse.  We examined the characteristics, 
healthcare utilization and survival of younger versus older patients with HF. 
Methods. Analysis of linked administrative databases in Alberta, Canada. 34,548 patients with first 
hospitalization for HF as principal diagnosis were identified from 2002 to 2014. Patients were stratified into 
four age groups: 20-44, 45-54, 55-64, and ≥65 years. 
Results.  Of the 34548 patients, 496 (1.4%), 1319 (3.8%), 3359 (9.7%) and 29374 (85%) patients were aged 
20-44, 45-54, 55-64 and ≥65 years, respectively. Incidence of HF hospitalization decreased over time among 
patients ≥65 years, and increased among men aged 20 – 64 years.  In the year following the index HF 
hospitalization, younger compared to older patients were less likely to present to the emergency department 
(ED) (e.g. 67.2% of those aged 20-44 years vs. 74.8% of those aged ≥65 years) or be hospitalized: for any 
reason (48.5% vs. 61.2%), cardiovascular causes (28.6% vs. 34.4%), or HF (14.8% vs. 23.6%). Mortality 
rates were lower in younger patients aged 20-44 years, but still substantial: 3.9%, 12.4%, and 27.7% at 30 
days, 1 year, and 5 years respectively. 
Conclusions. Although young patients, especially those <45 years of age, accounted for a small proportion 
of the total population, adverse events were frequent, with half of the younger patients being readmitted, two 
thirds presenting to an ED, and over 10% dying within a year.  
 
 
Word count: 234 
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Introduction 
 Heart failure (HF) is a major public health issue whose disease burden increases with 
advancing age.1,2 Most studies utilizing Medicare or administrative claims data have examined patients 65 
years or older and have often relied on hospitalization data alone.3,4 Younger patients (<65 years) with HF 
are less well characterized, particularly with respect to the interplay between their attendance at outpatient 
clinics, emergency departments (EDs), and hospitals. Accordingly, we examined the characteristics, 
resource utilization, and outcomes in young versus older patients with HF in the province of Alberta, 
Canada.5  
 
Methods 
Databases 
We linked the following five databases maintained by the Alberta Ministry of Health:6,7 1) the 
Discharge Abstract Database records information for all acute care hospitalizations (dates, principal 
diagnosis and up to 24 other diagnoses, procedures, length of stay and discharge status); 2) the Ambulatory 
Care Database records all visits to hospital-based physician offices or EDs and includes up to ten diagnosis 
fields; 3) the Practitioners Claims Database tracks all physicians’ claims from outpatient services and 
records up to 3 diagnostic codes per encounter; 4) the Population Registry records basic demographic and 
geographic information for all 4.1 million citizens; and 5) the Alberta Vital Statistics records all deaths in 
the province. Each patient has a unique personal identifier allowing linkage of patient information across the 
databases, but the data are released to researchers in de-identified form. 
 
Study population – incident and prevalent HF 
We identified all patients over 20 years of age hospitalized with HF as a principal diagnosis 
(International Classification of Disease, version 10 (ICD-10) code I50) between 1st April 2002 and 31st 
March 2014 in Alberta, Canada. The specificity and sensitivity of HF coding within the Alberta Health 
databases is 98.7% and 77.3% respectively.5,8 The first hospitalization with a principal diagnosis of HF 
during the study time period was considered the index hospitalization for each patient. Patients were 
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classified as either incident or prevalent HF patients at the time of their index hospitalization.  Incident 
patients were those without a prior diagnosis of HF recorded in all available data sources, including 
hospitalizations (1994 onwards), hospital based outpatient clinic or ED visits (1997 onwards), and physician 
office claims (1994 onwards). Prevalent patients were those with a prior diagnosis of HF in any setting, and 
were further categorized as those with or without previous HF hospitalization.  The HF incidence date for 
prevalent patients was the date of first diagnosis, regardless of setting. Concurrent hospitalizations or ED 
visits within 24 hours were considered the same episode of care.9 
 
Variables and Outcomes 
Comorbidities were identified using established ICD code case definitions previously validated in 
Alberta.8 They were considered to be present if recorded in any diagnostic position prior to hospitalization 
or in outpatient clinic/ED record.  If present only in physician office claims, a diagnosis had to be present in 
at least 5 claims to be considered a comorbidity. Annual median household income (MHI) in 2006 at the 
residential neighborhood level was obtained from census data from Statistics Canada. For prevalent patients, 
duration of disease was calculated as the number of days between the HF incidence date and the date of 
index HF hospitalization or first outpatient diagnosis. 
Outcomes of interest included one-year resource utilization among patients discharged alive from the 
index hospitalization, including all ED attendances and re-hospitalizations, and specifically those related to 
cardiovascular disease or HF. We also examined unadjusted rates and comorbidity adjusted odds ratios of 
in-hospital, 30-day, 1-year and 5-year mortality. 
 
Statistical analysis 
We stratified patients based on their age at first HF hospitalization into 4 age categories: 20-44, 45-
54, 55-64 and ≥65 years. Supplementary analyses by age and sex are provided in an online supplement.  We 
described baseline characteristics by age categories among incident and prevalent HF patients. Results are 
presented as means and standard deviations or medians and interquartile range for continuous variables and 
proportions for categorical variables. The incidence rate of HF was calculated as the number of incident 
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cases divided by the number of persons within each observation year by age category. Estimated counts of 
Alberta population for each observation year were extracted from databases maintained by Conference 
Board of Canada (http://www.conferenceboard.ca/). Poisson regression models were used to assess the trend 
of HF incidence rate by age category. Logistic regression models were used to estimate the odds ratio of 
younger age compared with the referent age category ≥65 years. The model was adjusted for comorbidities, 
annual median household income in 2006, urban residence, type of hospital, and year of admission. All tests 
were two sided with a level of significance set at P <0.05. Analyses were performed using SAS version 9.4.  
 
Results 
Between 1st April 2002 and 31st March 2014, 34,548 patients experienced an index HF admission. Of these, 
496 (1.4%), 1319 (3.8%) and 3359 (9.7%) patients were aged 20-44, 45-54 and 55-64 respectively. Those 
≥65 years accounted for 85.0% of the population. Overall, 23427 (67.8%) had a prior diagnosis of HF and 
11121 (32.2%) were incident presentations. The incidence of first HF hospitalization increased with 
increasing age (Table S1 in Supplementary Materials).  Although low, incidence rates among younger men 
(age 20 – 64 years) increased over time (from 1 per 10,000 in 2002/03 to 1.4 per 10,000 in 2012/13), but 
were stable among younger women.  In contrast, in patients ≥65 years, the incidence rates decreased over 
time among men and remained stable among women. 
 
Baseline characteristics of incident and prevalent patients, by age category, are presented in Table 1.  In both 
patient groups, except for rates of congenital heart disease and asthma, which were higher in the patients 
aged 20-44 and 45-54 years, rates of most comorbidities were higher in older patients. Younger patients had 
a shorter mean length of hospital stay compared to older patients, though median values were similar across 
age categories suggesting fewer very prolonged hospital admissions in younger patients.  In the subset of 
patients with prevalent HF who had been managed entirely in the outpatient setting prior to the index HF 
hospitalization, we examined the median days from diagnosis to hospitalization. The median (interquartile 
range) increased with increasing age: 139, (12 – 1030) in patients aged 20-44 years; 226 (24 – 1405) ages 
45–54; 405 (37 – 1528) ages 55–64; and 908 (140–2328) in those aged ≥65 years (p<0.0001)  
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Although the rates of subsequent ED presentations and re-hospitalizations within one year were lowest in 
younger patients, they were still substantial (Table 2). Approximately 70% of patients aged 20-44 years had 
a repeat ED visit compared with 75% of patients aged 65 years and rates of one-year re-hospitalization 
were approximately 50% and 60% in the two age groups, respectively. The in-hospital, 30 days, 1 and 5-
year mortality rates were 3.9%, 12.4%, and 27.7% in the youngest patients and 11.5%, 35.3%, and 72.8% in 
the oldest age group, respectively (Figure 1).  Differences in mortality between younger and older patients 
with HF remained even after adjustment for covariates (Table S2 in Supplementary Materials). All analyses 
stratified by sex and age category are presented in Tables S3 - S6 in Supplementary Materials. 
 
Discussion 
In this retrospective population-level cohort study, younger patients with HF had many important 
differences from their older counterparts. The incidence of HF hospitalization decreased over time among 
patients ≥65 years. Although low, incidence rates among younger men (age 20 – 64 years) increased over 
time but were stable among younger women. More than half of the younger patients had no prior history of 
HF in any setting, compared to just one quarter in those aged ≥65 years. For those with a prior diagnosis of 
HF in the outpatient setting, the time from diagnosis to first HF hospitalization was markedly shorter in 
younger compared to older patients.  HF in the young was associated with a significant mortality and 
morbidity burden with approximately 50% of young patients being readmitted to hospital, ~70% presenting 
to the emergency department, and 12% dying within one year of index HF hospitalization. 
 As with previous studies, the incidence of first HF hospitalization in our study was lower in younger 
compared to older patients.10-22 In developed countries the incidence and mortality of HF has generally been 
decreasing, leading to stable prevalence rates.23-25 The elderly have experienced the greatest decline in 
incidence, reflecting improved control of risk factors such as hypertension and diabetes,26,27 together with a 
declining incidence of myocardial infarction.28,29 We observed a rise in incident HF among younger men 
(but not women) in Alberta.  This is consistent with the findings from Sweden where the incidence of first 
HF hospitalization increased significantly from 1987-91 to 2002-2006 in those <54 years, relatively more so 
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in men compared to women.10 The extent to which sex differences observed in our study and the Swedish 
registry are attributable to male predominance of drug abuse and excessive alcohol consumption require 
further study. 
Previous studies of young patients with HF have largely been limited to hospitalizations,10,12 with a 
few linked to ambulatory clinic visits.17 To our knowledge, this is the only study to examine what appears to 
be a complex utilization pattern of ED services. After receiving an outpatient diagnosis of HF, we found 
young patients were admitted to hospital much sooner than older patients. Some plausible explanations for 
this finding is the different etiologies of HF in younger patients, including congenital heart disease and 
inherited cardiomyopathy. The population of adults with congenital heart disease is growing exponentially.  
This poses significant risk of adverse events including arrhythmia and heart failure and requires lifelong 
cardiology care. Transitions from pediatric to adult services are a recognized care gap, with up to half of 
patients not receiving appropriate follow-up.30  Mutations such as cardiac troponin T or β-myosin heavy 
chain cause early onset ventricular dysfunction.31-33 X-linked laminopathies and dystrophin defects may also 
contribute.34,35 In other cohorts, ejection fraction is lowest in younger patients (EF was unavailable in our 
administrative dataset), potentially prompting physicians to admit them sooner.36,37 Unlike older patients 
who may more readily attribute HF symptoms and functional limitation to age, younger patients with higher 
societal and family demands may be more likely to seek medical attention sooner. 
After discharge from first HF hospitalization, younger patients had lower readmission rates to 
hospital than older patients. This may reflect atypical presentation in younger patients, who are less likely to 
have peripheral edema, pulmonary rales, and radiological evidence of pulmonary edema.36 Physicians may 
be reassured by the absence of classical symptoms and signs and therefore discharge patients from the ED. 
Younger patients also have fewer comorbidities and less frailty, perhaps encouraging discharge and 
outpatient management. Nevertheless, young patients still had re-hospitalization rates by 1 year of 
approximately 50% for any cause and 15% for HF. 
Mortality data in young patients with HF are scarce.10,12,24 One-year case fatality after first 
hospitalization in the Swedish national registry was 11% to 12% in age groups from 18 to 54 years,10 and 
13% in the New South Wales study for those age 45-49 years.12 We found five-year mortality rates of 28%, 
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32% and 42% among patients aged 20-44, 45-54, and 55-64 years, respectively. Our results provide a guide 
to counsel patients with respect to longer term prognosis.  
 
Limitations 
 The linked administrative datasets in Alberta allow capture and follow-up of all interactions within 
the health care system. However, some limitations warrant consideration. The diagnosis of HF in hospital 
administrative registries relies on the accuracy of patient records and the responsible physicians. However, 
the accuracy of Alberta administrative data has been validated in patients with HF and for comorbidities. 
Data on ejection fraction, laboratory results, biomarkers, causes of HF are lacking. The number of younger 
patients is relatively small, increasing imprecision in results.  
 
Conclusions 
Compared to the elderly, younger patients with HF are more likely to present initially to secondary 
care, and be hospitalized sooner if diagnosed in primary care. Short and long-term mortality among young 
patients with HF remains high.  After discharge, over half of the young patients with HF are readmitted and 
over two thirds present to an ED within a year. The high mortality and adverse outcomes rates are a major 
cause for concern, and warrant a better understanding. 
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Figure legends 
 
Figure 1. Unadjusted 30 days, 1 and 5-year case fatality by age category among patients hospitalized with 
heart failure 
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Table 1. Baseline characteristics of hospitalized HF patients by age categories  
 
 INCIDENT HF PATIENTS1 PREVALENT HF PATIENTS2 
Age 20-44 45-54 55-64 ≥65 20-44 45-54 55-64 ≥65 
n 293 677 1467 8684 203 642 1892 20690 
Male 59.3 50.2 43.2 28.5 40.7 49.8 56.8 71.5 
Co-morbidities n (%)         
Prior MI 7 (2.4) 54 (8.0) 207 (14.1) 1470 (16.9) 29 (14.3) 204 (31.8) 732 (38.7) 8088 (39.1) 
Prior Revasc. 6 (2.0) 47 (6.9) 178 (12.1) 935 (10.8) 12 (5.9) 143 (22.3) 533 (28.2) 4246 (20.5) 
AF 49 (16.7) 157 (23.2) 398 (27.1) 3623 (41.7) 59 (29.1) 219 (34.1) 822 (43.4) 12494 (60.4) 
Hypercholesterolemia 8 (2.7) 52 (7.7) 184 (12.5) 1099 (12.7) 13 (6.4) 123 (19.2) 417 (22.0) 3948 (19.1) 
Hypertension 125 (42.7) 396 (58.5) 1033 (70.4) 7061 (81.3) 98 (48.3) 473 (73.7) 1602 (84.7) 18550 (89.7) 
CVD 12 (4.1) 58 (8.6) 159 (10.8) 1936 (22.3) 19 (9.4) 72 (11.2) 381 (20.1) 6127 (29.6) 
Diabetes mellitus 64 (21.8) 238 (35.2) 659 (44.9) 3145 (36.2) 55 (27.1) 317 (49.4) 1108 (58.6) 8765 (42.4) 
Malignant disease 9 (3.1) 52 (7.7) 158 (10.8) 1586 (18.3) 9 (4.4) 31 (4.8) 185 (9.8) 4005 (19.4) 
PAD 7 (2.4) 44 (6.5) 154 (10.5) 1432 (16.5) 21 (10.3) 92 (14.3) 434 (22.9) 5374 (26.0) 
Renal failure 34 (11.6) 84 (12.4) 195 (13.3) 1652 (19.0) 45 (22.2) 156 (24.3) 521 (27.5) 6920 (33.4) 
COPD 101 (34.5) 249 (36.8) 634 (43.2) 3640 (41.9) 91 (44.8) 350 (54.5) 1133 (59.9) 12383 (59.9) 
Asthma 58 (19.8) 110 (16.2) 199 (13.6) 931 (10.7) 48 (23.6) 154 (24.0) 413 (21.8) 3490 (16.9) 
CHD 33 (11.3) 30 (4.4) 22 (1.5) 111 (1.3) 50 (24.6) 57 (8.9) 106 (5.6) 537 (2.6) 
Type of hospital         
Community small 48 (16.4) 146 (21.6) 345 (23.5) 2252 (25.9) 34 (16.7) 137 (21.3) 486 (25.7) 6011 (29.1) 
Community medium 17 (5.8) 40 (5.9) 92 (6.3) 471 (5.4) 17 (8.4) 56 (8.7) 117 (6.2) 1102 (5.3) 
Community large 58 (19.8) 111 (16.4) 250 (17.0) 1499 (17.3) 33 (16.3) 101 (15.7) 295 (15.6) 3611 (17.5) 
Teaching 170 (58.0) 380 (56.1) 780 (53.2) 4462 (51.4) 119 (58.6) 348 (54.2) 994 (52.5) 9966 (48.2) 
Concurrent ED 273 (93.2) 617 (91.1) 1338 (91.2) 7929 (91.3) 163 (80.3) 497 (77.4) 1586 (83.8) 18164 (87.8) 
LOS, (Med, IQR) 8 (4, 13) 7 (5, 13) 8 (5, 13) 8 (5, 15) 7 (3, 11) 7 (4, 12) 7 (4, 13) 8 (5, 16) 
MHI  
59217  
(52216, 72202) 
58559  
(52162, 67440) 
58559  
(52162, 67440) 
58559  
(52046, 67074) 
58727  
(52162, 69101) 
58559  
(52162, 68487) 
58307  
(52162, 67054) 
57435  
(52046, 65726) 
Urban residence 236 (80.6) 527 (77.8) 1087 (74.1) 6813 (78.5) 158 (77.8) 472 (73.5) 1380 (72.9) 15769 (76.2) 
MI=myocardial infarction; Revasc.: Revascularization; AF=atrial fibrillation; CVD= cerebrovascular disease; PAD=peripheral arterial disease; COPD=chronic obstructive 
pulmonary disease; CHD: Congenital Heart Disease; ED: Emergency Department; LOS: Length of stay; Med: Median; IQR=inter-quartile range; MHI: Median Household 
Income 
1: Defined as patients without any prior diagnosis of HF in a physician’s office, outpatient clinic, emergency department, or hospital 
2: Defined as patients with a prior diagnosis of HF in a physician’s office, outpatient clinic, emergency department, or hospital
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Table 2. One-year non-fatal outcomes by age categories in patients discharged alive from HF hospitalization 
 
Age 20-44 45-54 55-64 ≥65 
n discharged alive 433 1164 2913 23281 
Any ED visit 291 (67.2) 763 (65.5) 2018 (69.3) 17415 (74.8) 
% followed by 
hospitalization 
105 (24.2) 287 (24.7) 816 (28.0) 8355 (35.9) 
Median days to event 
(IQR) 
46 (13, 131) 49 (10, 135) 47 (13, 135) 47 (14, 130) 
HF ED visit 77 (17.8) 197 (16.9) 630 (21.6) 6126 (26.3) 
% followed by 
hospitalization 
48 (11.1) 117 (10.1) 411 (14.1) 4107 (17.6) 
CV ED visit 133 (30.7) 366 (31.4) 1018 (34.9) 8797 (37.8) 
% followed by 
hospitalization 
69 (15.9) 191 (16.4) 577 (19.8) 5514 (23.7) 
Any re-hospitalization 210 (48.5) 572 (49.1) 1571 (53.9) 14252 (61.2) 
Median days to event 59 (18, 137) 70 (19, 167) 72 (22, 169) 67 (22, 166) 
CV re-hospitalization 124 (28.6) 327 (28.1) 932 (32.0) 8019 (34.4) 
Median days to event 61 (18, 145) 72 (19, 176) 87 (26, 194) 74 (24, 178) 
HF re-hospitalization 64 (14.8) 171 (14.7) 526 (18.1) 5496 (23.6) 
Median days to event 65 (18, 113) 61 (17, 171) 84 (24, 179) 71 (22, 175) 
 
N (%) or median (IQR) 
CV=cardiovascular; ED=emergency department; HF=heart failure; IQR=interquartile range.  
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Figure 1. Unadjusted 30 days, 1 and 5-year case fatality by age category among patients hospitalized with 
heart failure 
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Table S1. Incidence (per 10000 population) of HF hospitalization by age category 
 
Age 
 
2002/
03 
2003/ 
04 
2004/ 
05 
2005/ 
06 
2006/ 
07 
2007/ 
08 
2008/ 
09 
2009/ 
10 
2010/ 
11 
2011/ 
12 
2012/ 
13 
2013/ 
14 
P 
value 
Overall              
20-44 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.3 0.2 0.2 0.53 
45-54 1.3 1.0 0.9 1.2 0.9 0.9 1.3 1.2 0.9 0.9 1.2 1.1 0.81 
55-64 3.9 4.6 3.7 3.6 2.6 2.6 3 3.6 3.6 3.4 3.5 3.4 0.12 
20-64 0.9 1.0 0.8 0.9 0.8 0.7 0.9 0.1 0.9 1.0 1.0 1.0 0.13 
≥65 22.2 22.7 21.6 20.9 17.2 17.1 16.7 17.3 18.1 19.4 19.5 20.1 <0.01 
Men              
20-44 0.2 0.1 0.2 0.2 0.3 0.2 0.1 0.1 0.2 0.3 0.3 0.3 0.09 
45-54 1.2 1 0.9 1.5 1.2 1.3 1.8 1.6 0.9 1.1 1.7 1.3 0.16 
55-64 4.6 6 4.5 4 3.1 3.3 4.1 4.6 4.3 4 4.7 4.3 0.57 
20-64 1.0 1.1 0.9 1.1 0.9 0.9 1.1 1.2 1.0 1.1 1.4 1.2 <0.01 
≥65 22.2 23.1 24.9 22.3 17.4 17.3 19 17 16.9 19.1 18.8 20.7 <0.01 
Women              
20-44 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.26 
45-54 1.3 0.9 0.9 0.8 0.7 0.5 0.7 0.9 0.9 0.7 0.6 0.9 0.14 
55-64 3.1 3.3 2.9 3.2 2.2 1.9 1.9 2.6 2.8 2.7 2.2 2.4 0.06 
20-64 0.9 0.8 0.8 0.7 0.6 0.5 0.6 0.7 0.8 0.8 0.6 0.7 0.25 
≥65 22.3 22.4 18.9 19.7 17 17 14.9 17.6 19 19.8 20.1 19.6 0.10 
 
  
Table S2. Unadjusted and adjusted outcomes stratified by age categories among patients hospitalized with 
HF 
 
Age 20-44 45-54 55-64 ≥65 
In-hospital     
Population n 496 1319 3359 29374 
Death (%) 3.4 2.4 3.7 12.3 
OR (95% CI) 0.29 (0.18 , 0.47) 0.21 (0.15 , 0.30) 0.33 (0.27 , 0.40) 1 
30 days     
Population n 487 1279 3265 28509 
Death (%) 3.9 2.4 4.0 11.5 
OR (95% CI) 0.34 (0.21 , 0.54) 0.22 (0.15 , 0.32) 0.37 (0.31 , 0.45) 1 
Death/readmission  
n (%) 
89/469 (19.0) 202/1241 (16.3) 583/3127 (18.6) 5355/24892 (21.5) 
OR (95% CI) 0.99 (0.78 , 1.26) 0.80 (0.68 , 0.93) 0.91 (0.82 , 1.00) 1 
1 year     
Population n 434 1169 2965 26034 
Death (%) 12.4 10.6 16.6 35.3 
OR (95% CI) 0.31 (0.23 , 0.41) 0.27 (0.22 , 0.32) 0.43 (0.39 , 0.48) 1 
Death/readmission  
n (%) 
214/417 (51.3) 576/1134 (50.8) 1620/2839 (57.1) 15279/22694 (67.3) 
OR (95% CI) 0.72 (0.58 , 0.88) 0.64 (0.56 , 0.72) 0.74 (0.68 , 0.81) 1 
5 years     
Population n 260 738 1776 16536 
Death (%) 27.7 32.1 41.9 72.8 
OR (95% CI) 0.21 (0.16 , 0.28) 0.24 (0.20 , 0.28) 0.32 (0.29 , 0.36) 1 
Death/readmission  
n (%) 
188/249 (75.5) 564/708 (79.7) 1494/1694 (88.2) 13574/14377 (94.4) 
OR (95% CI) 0.35 (0.26 , 0.49) 0.34 (0.28 , 0.42) 0.54 (0.45 , 0.64) 1 
 
CI=confidence interval; OR=odd ratio. 
 
Variables include urban residence, prevalent episode, fiscal year of episode end date, presentation hospital 
(community small, community medium, community large, and teaching hospital), median household income, prior 
MI, prior revascularization, atrial fibrillation, cholesterol, hypertension, cerebo-vascular disease, diabetes mellitus, 
cancer, peripheral vascular disease, renal disease, COPD, asthma, and chronic heart disease. 
Death/readmission post discharge is assessed only for patients that were discharged alive from the index 
hospitalization episode, within 30 days post discharge
Table S3. Baseline characteristics by sex and age categories of incident HF patients 
 
Age 20-44  45-54  55-64  ≥65  
 M F M F M F M F 
n 178 115 425 252 922 545 3998 4686 
% (all incident and 
prevalent) 
59.3 58.7 50.2 53.4 43.2 44.6 28.5 30.6 
Co-morbidities (%)         
Prior MI 2.2 2.6 9.6 5.2 16.9 9.4 21.6 12.9 
Prior revascularization 2.2 1.7 8.7 4.0 15.5 6.4 15.3 6.9 
AF 20.8 10.4 28.0 15.1 31.1 20.4 42.4 41.1 
Hypercholesterolemia 3.4 1.7 9.4 4.8 13.7 10.6 13.8 11.7 
Hypertension 43.3 41.7 59.3 57.1 70.1 71.0 78.6 83.6 
CVD 3.9 4.3 8.2 9.1 11.3 10.1 22.5 22.2 
Diabetes mellitus 20.2 24.3 35.1 35.3 46.0 43.1 39.4 33.5 
Malignant disease 1.1 6.1 3.5 14.7 10.0 12.1 22.8 14.4 
PAD 2.2 2.6 7.5 4.8 11.3 9.2 19.5 13.9 
Renal failure 11.2 12.2 14.4 9.1 13.9 12.3 21.2 17.2 
COPD 30.9 40.0 31.8 45.2 38.9 50.5 45.1 39.2 
Asthma 17.4 23.5 10.1 26.6 9.4 20.6 9.3 11.9 
Congenital heart disease 12.9 8.7 4.5 4.4 1.3 1.8 1.3 1.3 
Type of presentation hospital 
Community small 15.2 18.3 23.1 19.0 23.6 23.3 26.5 25.5 
Community medium 5.1 7.0 5.6 6.3 6.3 6.2 6.4 4.6 
Community large 23.0 14.8 16.7 15.9 16.9 17.2 17.4 17.1 
Teaching 56.7 60.0 54.6 58.7 53.1 53.2 49.7 52.8 
Concurrent ED 91.6 95.7 90.1 92.9 91.1 91.4 90.9 91.7 
Length of stay         
Mean (SD) 10.6  
(10.2) 
10.7  
(14.0) 
12.4  
(26.7) 
10.1  
(10.1) 
13.3  
(20.4) 
13.4  
(19.5) 
14.7  
(23.1) 
16.2  
(24.3) 
Median (IQR) 8  
(5, 13) 
7  
(4, 11) 
7  
(5, 13) 
8  
(5, 12) 
8  
(5, 14) 
9  
(5, 13) 
8  
(4, 15) 
9  
(5, 16) 
Household income, Canadian dollars 
Median (IQR) 58928 
(52216, 
71759) 
59383 
(52162, 
73945) 
58307 
(52046, 
68487) 
58599 
(52249, 
67440) 
58559 
(52162, 
69101) 
58559 
(52216, 
67054) 
58559 
(52162, 
67054) 
58559 
(52001, 
67074) 
AF=atrial fibrillation; COPD=chronic obstructive pulmonary disease; CVD= cerebrovascular disease; IQR=inter-
quartile range; MI=myocardial infarction; PAD=peripheral arterial disease 
  
Table S4. Baseline characteristics by sex and age categories of patients with prevalent HF 
 
Age 20-44  45-54  55-64  ≥65  
 M F M F M F M F 
N 122 81 422 220 1214 678 10049 10641 
% (all incident and 
prevalent) 
40.7 41.3 49.8 46.6 56.8 55.4 71.5 69.4 
Co-morbidities         
Prior MI 13.1 16.0 35.5 24.5 45.4 26.7 47.0 31.6 
Prior revascularization 4.1 8.6 24.9 17.3 32.9 19.8 27.7 13.8 
AF 27.9 30.9 35.5 31.4 47.4 36.4 61.3 59.5 
Hypercholesterolemia 6.6 6.2 20.6 16.4 22.4 21.4 21.7 16.6 
Hypertension 44.3 54.3 73.0 75.0 84.4 85.1 87.8 91.4 
CVD 11.5 6.2 11.6 10.5 20.3 19.8 29.6 29.6 
Diabetes mellitus 21.3 35.8 48.1 51.8 56.2 62.8 45.2 39.7 
Malignant disease 2.5 7.4 4.5 5.5 9.6 10.2 23.2 15.7 
PAD 9.8 11.1 13.7 15.5 23.6 21.8 29.5 22.6 
Renal failure 18.9 27.2 23.2 26.4 26.7 29.1 37.0 30.1 
COPD 43.4 46.9 50.0 63.2 57.6 64.0 63.1 56.7 
Asthma 23.8 23.5 16.8 37.7 16.6 31.3 15.2 18.5 
Congenital heart disease 21.3 29.6 5.5 15.5 4.8 7.1 2.8 2.4 
Type of presentation hospital 
Community small 16.4 17.3 22.7 18.6 25.3 26.4 29.3 28.8 
Community medium 10.7 4.9 9.0 8.2 5.9 6.6 5.5 5.2 
Community large 14.8 18.5 15.4 16.4 14.6 17.4 17.3 17.6 
Teaching 58.2 59.3 52.8 56.8 54.2 49.6 47.9 48.4 
Concurrent ED 78.7 82.7 77.0 78.2 84.9 81.9 87.0 88.6 
Length of stay         
Mean (SD) 11.1  
(16.8) 
11.1  
(16.8) 
10.2  
(12.1) 
12.6  
(16.6) 
12.5  
(24.2) 
13.9  
(23.7) 
14.6  
(23.1) 
16.4  
(25.6) 
Median (IQR) 7  
(4, 11) 
7  
(3, 11) 
6  
(4, 11) 
7  
(5, 13) 
7  
(4, 13) 
8  
(4, 14) 
8  
(4, 15) 
8  
(5, 17) 
Household income, Canadian dollars 
Median (IQR) 58559 
(52046, 
69101) 
59383 
(53684, 
68271) 
58307 
(52162, 
68487) 
58579 
(52216, 
67964) 
58559 
(52162, 
68487) 
57256 
(52046, 
66577) 
57871 
(52162, 
65726) 
57435 
(52001, 
65282) 
AF=atrial fibrillation; COPD=chronic obstructive pulmonary disease; CVD= cerebrovascular disease; IQR=inter-
quartile range; MI=myocardial infarction; PAD=peripheral arterial disease 
Table S5. One-year non-fatal outcomes by sex and age categories in patients discharged alive from HF 
hospitalization 
 
Age 20-44  45-54  55-64  ≥65  
 M F M F M F M F 
n discharged alive 259 174 748 416 1857 1056 11062 12219 
Any ED visit 65.3 70.1 63.0 70.2 67.9 71.7 74.9 74.7 
% followed by 
hospitalization 
21.2 28.7 23.7 26.4 26.4 30.8 34.9 36.8 
Median days to event 
(IQR) 
59  
(12, 148) 
42  
(14, 102) 
51  
(11, 148) 
47  
(10, 126) 
48  
(13, 135) 
44  
(13, 135) 
46  
(13, 134) 
48  
(14, 127) 
HF ED visit 19.3 15.5 16.8 17.1 22.0 20.9 27.3 25.4 
% followed by 
hospitalization 
12.4 9.2 9.9 10.3 13.8 14.6 18.0 17.3 
CV ED visit 32.4 28.2 31.7 31.0 35.9 33.2 38.5 37.1 
% followed by 
hospitalization 
16.6 14.9 16.6 16.1 19.7 20.0 24.0 23.4 
Any re-hospitalization 49.0 47.7 47.9 51.4 52.8 56.0 61.6 60.9 
Median days to event 66  
(18, 174) 
56  
(19, 102) 
67  
(18, 173) 
81  
(19, 158) 
75  
(23, 168) 
68  
(20, 170) 
67  
(21, 164) 
69  
(23, 162) 
CV re-hospitalization 30.1 26.4 30.9 23.1 32.8 30.5 35.2 33.8 
Median days to event 64  
(18, 153) 
61  
(17, 118) 
67  
(19, 176) 
88  
(20, 178) 
90  
(26, 196) 
84  
(27, 190) 
77  
(24, 180) 
71  
(23, 176) 
HF re-hospitalization 15.1 14.4 16.3 11.8 17.7 18.8 23.9 23.3 
Median days to event 47  
(18, 103) 
83  
(42, 116) 
61  
(17, 171) 
65  
(21, 158) 
88  
(29, 180) 
73  
(22, 178) 
73  
(23, 177) 
70  
(22, 173) 
N (%) or median (IQR) 
CV=cardiovascular; ED=emergency department; HF=heart failure; IQR=interquartile range; SD=standard deviation.  
 
 
 
  
Table S6. Unadjusted and adjusted outcomes stratified by sex and age categories among patients 
hospitalized with HF 
 
Age 20-44  45-54  55-64  ≥65  
 M F M F M F M F 
In-hospital         
Population n 300 196 847 472 2136 1223 14047 15327 
Death (%) 2.7 4.6 2.1 3.0 3.2 4.7 12.3 12.2 
OR (95% CI) 0.22 
(0.20,0.79) 
0.40 
(0.20,0.79) 
0.19 
(0.12,0.30) 
0.26 
(0.15,0.45) 
0.29 
(0.22,0.37) 
0.41 
(0.31,0.54) 
1 1 
30 days         
Population n 296 191 819 460 2079 1186 13608 14901 
Death (%) 3.4 4.7 1.8 3.5 3.4 5.1 11.6 11.4 
OR (95% CI) 0.30 
(0.16,0.56) 
0.41 
(0.21,0.81) 
0.17 
(0.10,0.29) 
0.32 
(0.19,0.52) 
0.32 
(0.25,0.41) 
0.46 
(0.35,0.60) 
1 1 
Death/readmission  
n (%) 
53/286 
(18.5) 
36/183 
(19.7) 
129/800 
(16.1) 
73/441 
(16.6) 
369/2003 
(18.4) 
214/1124 
(19.0) 
2555/11874  
(21.5) 
2800/13018 
(21.5) 
OR (95% CI) 0.98 
(0.72,1.34) 
1.06 
(0.72,1.54) 
0.82 
(0.67,1.00) 
0.81 
(0.63,1.06) 
0.93 
(0.82,1.06) 
0.92 
(0.79,1.08) 
1 1 
1 year         
Population n 256 178 754 415 1875 1090 12398 13636 
Death (%) 11.3 14.0 10.6 10.6 15.7 18.1 36.2 34.5 
OR (95% CI) 0.28 
(0.19,0.41) 
0.36 
(0.23,0.56) 
0.27 
(0.21,0.34) 
0.27 
(0.19,0.37) 
0.41 
(0.36,0.46) 
0.48 
(0.40,0.56) 
1 1 
Death/readmission  
n (%) 
128/246 
(52.0) 
86/171 
(50.3) 
365/735 
(49.7) 
211/399 
(52.9) 
1018/1808 
(56.3) 
602/1031 
(58.4) 
7292/10778 
(67.7) 
7987/11916 
(67.0) 
OR (95% CI) 0.75 
(0.58,0.98) 
0.68 
(0.50,0.94) 
0.63 
(0.54,0.74) 
0.67 
(0.54,0.82) 
0.75 
(0.67,0.83) 
0.76 
(0.66,0.87) 
1 1 
5 years         
Population n 155 105 468 270 1114 662 7890 8646 
Death (%) 25.2 31.4 33.5 29.6 41.3 42.9 73.9 71.8 
OR (95% CI) 0.19 
(0.13,0.27) 
0.25 
(0.16,0.38) 
0.26 
(0.21,0.32) 
0.21 
(0.16,0.27) 
0.31 
(0.27,0.36) 
0.33 
(0.28,0.40) 
1 1 
 
CI=confidence interval; OR=odd ratio. 
 
Variables include prevalent episode, fiscal year of episode end date, presentation hospital (community small, 
community medium, community large, and teaching hospital), median household income, prior MI, prior 
revascularization, atrial fibrillation, cholesterol, hypertension, cerebo-vascular disease, diabetes mellitus, cancer, 
peripheral vascular disease, renal disease, COPD, asthma, and chronic heart disease. 
Death/readmission post discharge is assessed only for patients that were discharged alive from the index 
hospitalization episode, within 30 days post discharge. 
 
 
